GALDERMA LABORATORIES, L.P
PharmaGALDERMA LABORATORIES, L.P is a pharmaceutical company with 1 FDA-approved products.
GALDERMA LABORATORIES, L.P's Key Drugs
GALDERMA LABORATORIES, L.P's core commercial portfolio centers on DIFFERIN EPIDUO ACNE GEL (ADAPALENE AND BENZOYL PEROXIDE) — its most strategically important drugs approved in the last 15 years.
GALDERMA LABORATORIES, L.P's Recent FDA Approvals
GALDERMA LABORATORIES, L.P secured 1 new FDA approval for novel drugs (NDA/BLA) in the last two years.
GALDERMA LABORATORIES, L.P's Therapeutic Areas
Disease areas where GALDERMA LABORATORIES, L.P has approved drugs and an active pipeline. Weighted by commercial stage — approved drugs count most, then late-stage trials.
GALDERMA LABORATORIES, L.P Pipeline Snapshot
Active clinical trials for GALDERMA LABORATORIES, L.P across all therapeutic areas, from ClinicalTrials.gov.
Pro Intelligence Preview
Deep insights for investors and analysts
Revenue Insights
- • DIFFERIN EPIDUO ACNE GEL (ADAPALENE AND BENZOYL PEROXIDE) leads revenue
- • Drug-level revenue analysis
Trial Catalysts
- • Active trial monitoring
- • Phase 3 readout tracking
Patent Risk
- • Patent expiration timeline
- • Revenue at risk analysis
Compare Companies
- • Side-by-side pipeline analysis
- • Revenue & market share comparison
Revenue forecasts • Trial milestones • Patent risk modeling
Discontinued (0)
Company Info
- First Approval
- 2026-05-22
- Latest
- 2026-05-22
- Applications
- 1